Synthetic immune approaches remain at the forefront, offering precise and powerful strategies for targeting and eliminating cancer cells. This webcast dives into the distinct contrasts in functionality and future prospects of CAR-T and T-Cell Engagers (TCE) as single agents and in combination therapies. Exploring how these approaches function, the discussion will focus on shedding light on the unique features of CAR-T and TCE and what lies ahead for their application in the evolving landscape of cancer treatment, particularly in addressing solid tumors. While both utilize a T cell’s killing machinery, understanding these contrasts is crucial for shaping the future of cancer immunotherapy.
- Gain insights into the shared and contrasting mechanisms, technologies, and approaches in CAR-T and TCE
- Identify the unique features and future prospects of CAR-T and TCE as single agents and in combination therapies
- Explore the implications of these contrasts in addressing the challenges of solid tumor treatment
- Deepen understanding of the evolving landscape of cancer immunotherapy and the role of CAR-T and TCE in shaping its future